Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245997 · ClinicalTrials.gov registry record · Early Phase 1
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
A Early Phase 1 study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT02245997 is a Early Phase 1 study of Neuroblastoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 78 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02245997, a Early Phase 1 study of Neuroblastoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to give 12T a smaller dose of radiation in order to decrease these late side effects.
Conditions Studied
Interventions
- RADIATION External beam radiotherapy
- RADIATION proton beam RT
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2014-09 |
| Est. Completion | 2025-05-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02245997
The ClinicalTrials.gov registry entry for NCT02245997 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (67% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 2 interventions - of which External beam radiotherapy is the first listed.
NCT02245997 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02245997 about?
NCT02245997 is a clinical study titled "Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma". The purpose of this study is to give 12T a smaller dose of radiation in order to decrease these late side effects.
What is the current status of trial NCT02245997?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 78 participants. The study started on 2014-09. Estimated completion is 2025-05-01.
What conditions does trial NCT02245997 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT02245997?
The interventions under investigation include: External beam radiotherapy (RADIATION), proton beam RT (RADIATION).
Who is sponsoring clinical trial NCT02245997?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02245997 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of N9 Chemotherapy in Children With Neuroblastoma
ACTIVE NOT RECRUITING · Early Phase 1
-
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
ACTIVE NOT RECRUITING · Early Phase 1
-
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.